{"id":439845,"date":"2021-02-19T08:03:27","date_gmt":"2021-02-19T13:03:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=439845"},"modified":"2021-02-19T08:03:27","modified_gmt":"2021-02-19T13:03:27","slug":"blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/","title":{"rendered":"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">PHILADELPHIA<\/span>, <span class=\"xn-chron\">Feb. 19, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. (&#8220;bluebird&#8221; or the &#8220;Company&#8221;) on behalf of investors who purchased bluebird securities (NASDAQ: BLUE) between <b><span class=\"xn-chron\">May 11, 2020<\/span> and <span class=\"xn-chron\">November 4, 2020<\/span><\/b> (the &#8220;Class Period&#8221;). <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" title=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" alt=\"A national class action and commercial litigation law firm with nationally known attorneys highly sought after for their legal skills. (PRNewsFoto\/Berger Montague)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>If you purchased bluebird securities during the Class Period, have questions concerning your rights or interests, or would like to discuss <span class=\"xn-person\">Berger Montague&#8217;s<\/span> investigation, please contact attorneys <span class=\"xn-person\">Andrew Abramowitz<\/span> at <a target=\"_blank\" href=\"mailto:aabramowitz@bm.net\" rel=\"nofollow noopener noreferrer\">aabramowitz@bm.net<\/a>\u00a0or (215) 875-3015, or <span class=\"xn-person\">Donnell Much<\/span> at <a target=\"_blank\" href=\"mailto:dmuch@bm.net\" rel=\"nofollow noopener noreferrer\">dmuch@bm.net<\/a>\u00a0or (215) 875-4667, or contact us at: <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3072203-1&amp;h=4104702172&amp;u=https%3A%2F%2Fwww.bergermontague.com%2Fbluebird&amp;a=www.bergermontague.com%2Fbluebird\" rel=\"nofollow noopener noreferrer\">www.bergermontague.com\/bluebird<\/a>. <\/p>\n<p>According to a recently filed lawsuit, defendants misled investors during the Class Period by, among other things: (i) failing to disclose that the data supporting bluebird&#8217;s Biologics License Application (&#8220;BLA&#8221;) submission for LentiGlobin, a gene therapy intended to treat sickle cell disease, was insufficient to demonstrate drug product comparability; (ii) downplaying the potential impact of COVID-related disruptions on the Company&#8217;s BLA submission schedule; and (iii) failing to inform the market that it was foreseeable that bluebird would not submit the BLA for LentiGlobin in the second half of 2021.<\/p>\n<p>The lawsuit alleges that investors learned the truth on\u00a0November 4, 2020, when bluebird disclosed that it would no longer submit its BLA for LentiGlobin in the second half of 2021. Instead, citing &#8220;feedback&#8221; from the FDA requiring the Company to provide additional data demonstrating &#8220;drug product comparability,&#8221; as well as COVID-related &#8220;shifts and contract manufacturing&#8221; impacts, bluebird adjusted its submission timing to late 2022.<\/p>\n<p>On this news, bluebird&#8217;s stock price fell\u00a0$9.72\u00a0per share, or 16.6%, to close at\u00a0$48.83\u00a0per share on\u00a0November 5, 2020.<\/p>\n<p>If you purchased bluebird securities during the Class Period, you may seek Court appointment as lead plaintiff to represent other injured investors in a class action. The lead plaintiff appointment deadline is <b><span class=\"xn-chron\">April 13, 2021<\/span>.<\/b> You do not need to be a lead plaintiff to share in any potential Class recovery.<\/p>\n<p>\n        <b>Whistleblowers:\u00a0<\/b>Persons with non-public information regarding bluebird are encouraged to confidentially assist <span class=\"xn-person\">Berger Montague&#8217;s<\/span> investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.<\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3072203-1&amp;h=1486720181&amp;u=https%3A%2F%2Fbergermontague.com%2F&amp;a=Berger+Montague\" rel=\"nofollow noopener noreferrer\"><br \/>\n          <span class=\"xn-person\">Berger Montague<\/span><br \/>\n        <\/a>, with offices in <span class=\"xn-location\">Philadelphia<\/span>, <span class=\"xn-location\">Minneapolis<\/span>, <span class=\"xn-location\">Washington, D.C.<\/span>, and <span class=\"xn-location\">San Diego<\/span>, has been a pioneer in securities class action litigation since its founding in 1970. <span class=\"xn-person\">Berger Montague<\/span> has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Andrew Abramowitz<\/span>, Senior Counsel<br \/><span class=\"xn-person\">Berger Montague<\/span><br \/>(215) 875-3015<br \/><a target=\"_blank\" href=\"mailto:aabramowitz@bm.net\" rel=\"nofollow noopener noreferrer\">aabramowitz@bm.net<\/a>\u00a0\u00a0<\/p>\n<p>\n        <span class=\"xn-person\">Donnell Much<\/span>, Associate<br \/><span class=\"xn-person\">Berger Montague<\/span><br \/>(215) 875-4667<br \/><a target=\"_blank\" href=\"mailto:dmuch@bm.net\" rel=\"nofollow noopener noreferrer\">dmuch@bm.net<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC84347&amp;sd=2021-02-19\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021-301231474.html\">http:\/\/www.prnewswire.com\/news-releases\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021-301231474.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Berger Montague<\/span><\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC84347&amp;Transmission_Id=202102190800PR_NEWS_USPR_____DC84347&amp;DateId=20210219\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire PHILADELPHIA, Feb. 19, 2021 \/PRNewswire\/ &#8212;\u00a0Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. (&#8220;bluebird&#8221; or the &#8220;Company&#8221;) on behalf of investors who purchased bluebird securities (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020 (the &#8220;Class Period&#8221;). If you purchased bluebird securities during the Class Period, have questions concerning your rights or interests, or would like to discuss Berger Montague&#8217;s investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net\u00a0or (215) 875-3015, or Donnell Much at dmuch@bm.net\u00a0or (215) 875-4667, or contact us at: www.bergermontague.com\/bluebird. According to a recently filed lawsuit, defendants misled investors during the Class Period by, among other things: (i) failing to disclose that the data supporting bluebird&#8217;s Biologics License Application (&#8220;BLA&#8221;) submission &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-439845","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PHILADELPHIA, Feb. 19, 2021 \/PRNewswire\/ &#8212;\u00a0Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. (&#8220;bluebird&#8221; or the &#8220;Company&#8221;) on behalf of investors who purchased bluebird securities (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020 (the &#8220;Class Period&#8221;). If you purchased bluebird securities during the Class Period, have questions concerning your rights or interests, or would like to discuss Berger Montague&#8217;s investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net\u00a0or (215) 875-3015, or Donnell Much at dmuch@bm.net\u00a0or (215) 875-4667, or contact us at: www.bergermontague.com\/bluebird. According to a recently filed lawsuit, defendants misled investors during the Class Period by, among other things: (i) failing to disclose that the data supporting bluebird&#8217;s Biologics License Application (&#8220;BLA&#8221;) submission &hellip; Continue reading &quot;BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-19T13:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021\",\"datePublished\":\"2021-02-19T13:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/\"},\"wordCount\":463,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/\",\"name\":\"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"datePublished\":\"2021-02-19T13:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/232479\\\/berger_montague.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/","og_locale":"en_US","og_type":"article","og_title":"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021 - Market Newsdesk","og_description":"PR Newswire PHILADELPHIA, Feb. 19, 2021 \/PRNewswire\/ &#8212;\u00a0Berger Montague is investigating potential securities fraud claims against bluebird bio, Inc. (&#8220;bluebird&#8221; or the &#8220;Company&#8221;) on behalf of investors who purchased bluebird securities (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020 (the &#8220;Class Period&#8221;). If you purchased bluebird securities during the Class Period, have questions concerning your rights or interests, or would like to discuss Berger Montague&#8217;s investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net\u00a0or (215) 875-3015, or Donnell Much at dmuch@bm.net\u00a0or (215) 875-4667, or contact us at: www.bergermontague.com\/bluebird. According to a recently filed lawsuit, defendants misled investors during the Class Period by, among other things: (i) failing to disclose that the data supporting bluebird&#8217;s Biologics License Application (&#8220;BLA&#8221;) submission &hellip; Continue reading \"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-19T13:03:27+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021","datePublished":"2021-02-19T13:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/"},"wordCount":463,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/","name":"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","datePublished":"2021-02-19T13:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/232479\/berger_montague.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blue-stock-berger-montague-investigates-alleged-securities-fraud-claims-against-bluebird-bio-inc-nasdaq-blue-lead-plaintiff-deadline-is-april-13-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=439845"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439845\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=439845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=439845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=439845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}